To help you feel confident and prepared, weve compiled a list of resources tailored for patients starting GLP-1 Plus therapy
Across all six studies, the safety findings were consistent: no serious adverse events, no immunogenic responses, no changes in IGF-1, no glucose or insulin disruption
Gasseri and body composition, B
Alcohol Clin Exp Res 34:385395 Quddos F, Hubshman Z, Tegge A et al (2023) Semaglutide and Tirzepatide reduce alcohol consumption in individuals with obesity
However, unlike Ozempic and Wegovys active ingredient, tirzepatide works on a second hormone receptor, GIP (glucose-dependent insulinotropic polypeptide), which some studies suggest is more effective than semaglutide for blood sugar control and weight loss
Additionally, it has been suggested that GIPR agonists and antagonists might target different CNS receptor populations, with evidence showing that acylated peptide GIPR agonists act on GABAergic neurons to further reduce food intake and body weight when combined with GLP-1R agonists in mice 39,40